[Featured Stock] Jinwon Life Sciences Builds mRNA Vaccine Production Base with Hanmi... "Also Collaborating on COVID-19 Vaccine Commercialization"
[Asia Economy Reporter Hyunseok Yoo] Jinwon Life Sciences is showing strong performance. It appears to be influenced by the news of an agreement with Hanmi Science on mRNA vaccines.
As of 1:14 PM on the 31st, Jinwon Life Sciences was trading at 23,400 KRW, up 4.00% (900 KRW) compared to the previous trading day.
On this day, the two companies announced that they have embarked on establishing a large-scale production base and a global business network for mRNA vaccines. According to the contract, both companies plan to optimize their core technologies to research next-generation production technologies for large-scale manufacturing of mRNA vaccines.
They will also become partners in building a comprehensive global nucleic acid business network, including joint research and commercialization of mRNA vaccines for new infectious diseases such as COVID-19.
Hot Picks Today
!["Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①](https://cwcontent.asiae.co.kr/asiaresize/93/2026051914165468840_1779167814.png)
"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- "I'll Stop by Starbucks Tomorrow": People Power Chungbuk Committee and Geoje Mayoral Candidate Face Criticism for Alleged 5·18 Demeaning Remarks
- Woman Experiences Eye Protrusion After 20 Years of Contraceptive Injections, Plans Lawsuit Against Major Pharmaceutical Company
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
Currently, Jinwon Life Sciences is conducting clinical development of DNA vaccines for prevention of COVID-19, MERS, and hepatitis C. In addition to existing COVID-19 mRNA vaccines, they possess a pan-COVID-19 mRNA vaccine candidate that prevents virus mutations. Along with this, through its U.S. subsidiary VGXI, the company owns a cGMP-grade factory capable of contract manufacturing plasmid DNA and mRNA vaccine bulk materials, which are key raw materials for DNA vaccines and gene therapies.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
